This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.
CSL continues to deliver strong revenue growth, with solid demand for its products. Both plasma products and immunoglobulin are experiencing significant growth and the company continues to look for M&A growth opportunities. Additionally, it is well leveraged to a recovering US economy.
It seems every time the stock consolidates, it’s not long before a breakout comes to fruition. Between August and October, the stock was range bound within the $72-$75 region. Eventually, at the end of October it had enough conviction to knock through that barrier, taking the stock up to the $80 mark.
This level has since presented some challenges for CSL, resulting in a month-long consolidation between $78-$80. A darvis breakout formation now seems to be in play and this is could take CSL another leg higher. The key will be for CSL to close above $80.44 today, which is the October high. This would effectively be a darvis breakout. Traders could potentially buy the stock above $80.44, with stops placed in the $77.50 region. Given this is unchartered territory for the stock, targets will have to be assessed on the momentum of the trade.